Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Parallel-group, Clinical Study of S-649266 Compared With Meropenem for the Treatment of Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, or Healthcare-associated Bacterial Pneumonia Caused by Gram-negative Pathogens

Trial Profile

A Multicenter, Randomized, Double-blind, Parallel-group, Clinical Study of S-649266 Compared With Meropenem for the Treatment of Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, or Healthcare-associated Bacterial Pneumonia Caused by Gram-negative Pathogens

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cefiderocol (Primary) ; Linezolid; Meropenem
  • Indications Gram-negative infections; Nosocomial pneumonia
  • Focus Registrational; Therapeutic Use
  • Acronyms APEKS-NP
  • Sponsors Shionogi
  • Most Recent Events

    • 08 Oct 2019 According to a Shionogi media release, data from the study were presented as a late-breaking oral presentation at IDWeek 2019 on Thursday, October 3.
    • 02 Oct 2019 Primary endpoint has been met. (All-cause Mortality at Day 14), according to a Shionogi media release.
    • 02 Oct 2019 Results published in the Shionogi Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top